19-nor-1α,25-dihydroxyvitamin D2 (Paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo

Gary G. Schwartz, Dawn Eads, Christine Naczki, Scott Northrup, Tai Chen, Constantinos Koumenis

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

1,25-dihydroxyvitamin D3, (1,25(OH)2D3; calcitriol), the hormonal form of vitamin D, exerts growth-inhibitory, pro-apoptotic and anti-metastatic effects on tumor cells in vitro and in vivo but its clinical use is limited by its calcemic effects. Previous studies have shown that the antiproliferative effects of the less calcemic calcitriol analog 19-nor-1,25-(OH)2D2 (paricalcitol) on prostate tumor cell lines are indistinguishable from those of 1,25(OH)2D3. We therefore investigated the anti-proliferative effects of paricalcitol on the growth of pancreatic tumor cell lines in vitro and in vivo. Both 1,25(OH) 2D3 and paricalcitol inhibited the growth of BxPC-3, Hs700T and AsPC-1 lines in a dose-dependent manner. This antiproliferative activity correlated with upregulation of the cell cycle inhibitors p21 (Waf1/CIP1) and p27(Kip1). A fourth pancreatic cell line, Hs766T, was unresponsive to both paricalcitol and calcitriol. Hs766T cells also failed to upregulate p21/Waf-1/Cip1 or p27/KiP in response to treatments with these agents. Paricalcitol, given three times per week, inhibited the growth of AsPC-1 pancreatic tumor cell xenografts in nude mice at a dose that did not cause hypercalcaemia. Tumor inhibition was accompanied by in vivo upregulation of p21 and p27 expression. Given the few therapeutic options for patients with pancreatic cancer, further exploration of paricalcitol, an FDA-approved medication, is warranted.

Original languageEnglish (US)
Pages (from-to)430-436
Number of pages7
JournalCancer Biology and Therapy
Volume7
Issue number3
DOIs
StatePublished - Mar 2008

Fingerprint

Pancreatic Neoplasms
Calcitriol
Up-Regulation
Growth
Tumor Cell Line
Neoplasms
Hypercalcemia
In Vitro Techniques
1,25-dihydroxyergocalciferol
paricalcitol
Heterografts
Nude Mice
Vitamin D
Prostate
Cell Cycle
Cell Line
Therapeutics

Keywords

  • Pancreatic cancer
  • Vitamin D
  • Zemplar
  • p21
  • p27

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

19-nor-1α,25-dihydroxyvitamin D2 (Paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo. / Schwartz, Gary G.; Eads, Dawn; Naczki, Christine; Northrup, Scott; Chen, Tai; Koumenis, Constantinos.

In: Cancer Biology and Therapy, Vol. 7, No. 3, 03.2008, p. 430-436.

Research output: Contribution to journalArticle

Schwartz, Gary G. ; Eads, Dawn ; Naczki, Christine ; Northrup, Scott ; Chen, Tai ; Koumenis, Constantinos. / 19-nor-1α,25-dihydroxyvitamin D2 (Paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo. In: Cancer Biology and Therapy. 2008 ; Vol. 7, No. 3. pp. 430-436.
@article{f7b539bb5f30410f85206747e5405d4d,
title = "19-nor-1α,25-dihydroxyvitamin D2 (Paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo",
abstract = "1,25-dihydroxyvitamin D3, (1,25(OH)2D3; calcitriol), the hormonal form of vitamin D, exerts growth-inhibitory, pro-apoptotic and anti-metastatic effects on tumor cells in vitro and in vivo but its clinical use is limited by its calcemic effects. Previous studies have shown that the antiproliferative effects of the less calcemic calcitriol analog 19-nor-1,25-(OH)2D2 (paricalcitol) on prostate tumor cell lines are indistinguishable from those of 1,25(OH)2D3. We therefore investigated the anti-proliferative effects of paricalcitol on the growth of pancreatic tumor cell lines in vitro and in vivo. Both 1,25(OH) 2D3 and paricalcitol inhibited the growth of BxPC-3, Hs700T and AsPC-1 lines in a dose-dependent manner. This antiproliferative activity correlated with upregulation of the cell cycle inhibitors p21 (Waf1/CIP1) and p27(Kip1). A fourth pancreatic cell line, Hs766T, was unresponsive to both paricalcitol and calcitriol. Hs766T cells also failed to upregulate p21/Waf-1/Cip1 or p27/KiP in response to treatments with these agents. Paricalcitol, given three times per week, inhibited the growth of AsPC-1 pancreatic tumor cell xenografts in nude mice at a dose that did not cause hypercalcaemia. Tumor inhibition was accompanied by in vivo upregulation of p21 and p27 expression. Given the few therapeutic options for patients with pancreatic cancer, further exploration of paricalcitol, an FDA-approved medication, is warranted.",
keywords = "Pancreatic cancer, Vitamin D, Zemplar, p21, p27",
author = "Schwartz, {Gary G.} and Dawn Eads and Christine Naczki and Scott Northrup and Tai Chen and Constantinos Koumenis",
year = "2008",
month = "3",
doi = "10.4161/cbt.7.3.5418",
language = "English (US)",
volume = "7",
pages = "430--436",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "3",

}

TY - JOUR

T1 - 19-nor-1α,25-dihydroxyvitamin D2 (Paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo

AU - Schwartz, Gary G.

AU - Eads, Dawn

AU - Naczki, Christine

AU - Northrup, Scott

AU - Chen, Tai

AU - Koumenis, Constantinos

PY - 2008/3

Y1 - 2008/3

N2 - 1,25-dihydroxyvitamin D3, (1,25(OH)2D3; calcitriol), the hormonal form of vitamin D, exerts growth-inhibitory, pro-apoptotic and anti-metastatic effects on tumor cells in vitro and in vivo but its clinical use is limited by its calcemic effects. Previous studies have shown that the antiproliferative effects of the less calcemic calcitriol analog 19-nor-1,25-(OH)2D2 (paricalcitol) on prostate tumor cell lines are indistinguishable from those of 1,25(OH)2D3. We therefore investigated the anti-proliferative effects of paricalcitol on the growth of pancreatic tumor cell lines in vitro and in vivo. Both 1,25(OH) 2D3 and paricalcitol inhibited the growth of BxPC-3, Hs700T and AsPC-1 lines in a dose-dependent manner. This antiproliferative activity correlated with upregulation of the cell cycle inhibitors p21 (Waf1/CIP1) and p27(Kip1). A fourth pancreatic cell line, Hs766T, was unresponsive to both paricalcitol and calcitriol. Hs766T cells also failed to upregulate p21/Waf-1/Cip1 or p27/KiP in response to treatments with these agents. Paricalcitol, given three times per week, inhibited the growth of AsPC-1 pancreatic tumor cell xenografts in nude mice at a dose that did not cause hypercalcaemia. Tumor inhibition was accompanied by in vivo upregulation of p21 and p27 expression. Given the few therapeutic options for patients with pancreatic cancer, further exploration of paricalcitol, an FDA-approved medication, is warranted.

AB - 1,25-dihydroxyvitamin D3, (1,25(OH)2D3; calcitriol), the hormonal form of vitamin D, exerts growth-inhibitory, pro-apoptotic and anti-metastatic effects on tumor cells in vitro and in vivo but its clinical use is limited by its calcemic effects. Previous studies have shown that the antiproliferative effects of the less calcemic calcitriol analog 19-nor-1,25-(OH)2D2 (paricalcitol) on prostate tumor cell lines are indistinguishable from those of 1,25(OH)2D3. We therefore investigated the anti-proliferative effects of paricalcitol on the growth of pancreatic tumor cell lines in vitro and in vivo. Both 1,25(OH) 2D3 and paricalcitol inhibited the growth of BxPC-3, Hs700T and AsPC-1 lines in a dose-dependent manner. This antiproliferative activity correlated with upregulation of the cell cycle inhibitors p21 (Waf1/CIP1) and p27(Kip1). A fourth pancreatic cell line, Hs766T, was unresponsive to both paricalcitol and calcitriol. Hs766T cells also failed to upregulate p21/Waf-1/Cip1 or p27/KiP in response to treatments with these agents. Paricalcitol, given three times per week, inhibited the growth of AsPC-1 pancreatic tumor cell xenografts in nude mice at a dose that did not cause hypercalcaemia. Tumor inhibition was accompanied by in vivo upregulation of p21 and p27 expression. Given the few therapeutic options for patients with pancreatic cancer, further exploration of paricalcitol, an FDA-approved medication, is warranted.

KW - Pancreatic cancer

KW - Vitamin D

KW - Zemplar

KW - p21

KW - p27

UR - http://www.scopus.com/inward/record.url?scp=45349085534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45349085534&partnerID=8YFLogxK

U2 - 10.4161/cbt.7.3.5418

DO - 10.4161/cbt.7.3.5418

M3 - Article

C2 - 18094617

AN - SCOPUS:45349085534

VL - 7

SP - 430

EP - 436

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 3

ER -